8-K: Vivos Therapeutics Reports Strong Q2 2024 Results with Revenue Growth and Reduced Operating Expenses

Vivos Therapeutics announced a 19% increase in revenue and a 31% decrease in operating expenses for the second quarter of 2024, alongside a new strategic marketing alliance.

Summary

• Vivos Therapeutics reported a 19% increase in revenue both sequentially and year-over-year, reaching $4.1 million for the second quarter of 2024.
• The company's revenue for the first six months of 2024 was $7.5 million, compared to $7.3 million for the same period in 2023.
• Gross profit for Q2 2024 was $2.7 million, up from $2.1 million in Q2 2023, with a gross margin of 65%, compared to 62% in the prior year.
• Operating expenses decreased by 31% in Q2 2024 compared to Q2 2023, a reduction of $2.0 million, and by 26% for the first six months of 2024, a reduction of $3.7 million.
• The company's operating loss decreased by 57% in Q2 2024 compared to Q2 2023, and by 40% for the first six months of 2024.
• Vivos anticipates achieving positive cash flow in early 2025.
• As of June 30, 2024, Vivos had $6.9 million in cash and cash equivalents and $6.3 million in stockholders' equity.
• Over 45,000 patients have been treated with Vivos oral appliances worldwide, and more than 2,000 dentists have been trained in the Vivos Method.
• In April 2024, Vivos received Medicare reimbursement approval for its CARE oral devices.
• In June 2024, Vivos formed a strategic marketing alliance with a sleep testing and treatment center operator in Colorado and closed a $7.5 million equity growth investment.
• A marketing pilot showed that 79% of newly diagnosed OSA patients chose Vivos oral appliance therapy over CPAP or doing nothing.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, significant cost reductions, and a strategic investment. The company's new marketing model and positive pilot results further boost confidence. However, the net loss and accumulated deficit temper the overall sentiment slightly.

Positives

• Revenue increased by 19% both sequentially and year-over-year, indicating strong sales growth.
• Operating expenses decreased by 31% in Q2 2024, demonstrating successful cost-cutting initiatives.
• Gross margin improved to 65% in Q2 2024, reflecting better profitability.
• The company secured a $7.5 million equity investment, strengthening its financial position.
• Vivos received Medicare reimbursement approval for its CARE oral devices, expanding market access.
• A new strategic marketing alliance was formed, potentially increasing patient reach.
• A successful marketing pilot showed high patient preference for Vivos therapy.
• The company has treated over 45,000 patients and trained over 2,000 dentists, indicating strong market adoption.

Negatives

• The company reported a net loss of $1.93 million for the second quarter of 2024.
• Myofunctional therapy revenues decreased, partially offsetting gains in other areas.
• The company has an accumulated deficit of $98.744 million.

Risks

• The company may be unable to implement revenue, sales, and marketing strategies that increase revenues.
• Some patients may not achieve the desired results from using Vivos products.
• There are risks associated with regulatory scrutiny and adverse publicity in the sleep apnea treatment sector.
• Vivos may be unable to secure additional financing on reasonable terms or maintain its Nasdaq listing.
• The company's future success depends on the successful implementation of its new marketing and distribution model.

Future Outlook

Vivos anticipates achieving positive cash flow in early 2025 and expects its new marketing and distribution model to substantially expand the number of OSA patients who have access to its products and methods, making revenue less reliant on VIP enrollments.

Management Comments

• Kirk Huntsman, Vivos Chairman and Chief Executive Officer, stated, 'Today, we reported solid second quarter results as we continued to leverage our broad portfolio of innovative products, and our proprietary core technology and treatment protocols that offer highly effective treatment alternatives for OSA patients.'
• Mr. Huntsman also noted that the new marketing and distribution model is designed to better align interests with referring medical professionals, dentists, and sleep treatment providers.
• Mr. Huntsman concluded that Vivos offers adult patients who suffer from OSA an effective, safe, and non-surgical solution for all severities of this debilitating condition.

Industry Context

This announcement reflects a trend in the medical device industry towards more integrated and collaborative approaches to patient care, with a focus on expanding access to innovative treatments for sleep disorders. The strategic alliance with a sleep testing and treatment center operator is a move towards a more direct and vertically integrated model, which is becoming increasingly common in the healthcare sector.

Comparison to Industry Standards

• The 19% revenue growth is a strong result compared to many medical device companies, especially those in the sleep apnea space, which often see more modest growth rates.
• The 31% reduction in operating expenses is significant and suggests effective cost management, which is a key focus for many companies in the current economic climate.
• The gross margin of 65% is competitive within the medical device industry, indicating a healthy balance between revenue and cost of goods sold.
• The successful pilot program showing 79% patient preference for Vivos therapy is a strong indicator of product efficacy and market acceptance, which is a key differentiator compared to competitors offering CPAP or other treatment options.
• Companies like ResMed and Philips, which are major players in the sleep apnea market, have been focusing on similar strategies of expanding their reach through partnerships and innovative solutions, but Vivos's focus on a non-surgical approach provides a unique selling point.

Stakeholder Impact

• Shareholders will benefit from the increased revenue, reduced expenses, and strategic investment.
• Employees may experience job security due to the company's improved financial position.
• Customers (patients) will have increased access to Vivos's treatment options through the new marketing alliance.
• Suppliers may see increased demand for Vivos products.
• Creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• Vivos will continue to implement its new marketing and distribution model.
• The company will focus on expanding its relationships with medical specialists and sleep-related healthcare practitioners.
• Vivos will work with New Seneca Partners as an advisor to bolster growth prospects.
• The company will file its full 10-Q report with the SEC.
• Vivos will continue to monitor and manage its cash position and expenses to remain compliant with Nasdaq listing standards.

Key Dates

Keywords

Vivos Therapeutics, Obstructive Sleep Apnea, OSA, Medical Device, Oral Appliances, Sleep Apnea Treatment, Revenue Growth, Cost Cutting, Medicare Reimbursement, Strategic Alliance, Equity Investment